PTXPrescient Therapeutics
About Prescient Therapeutics
Prescient Therapeutics (ASX:PTX) is a clinical-stage biotechnology company developing innovative gene editing and gene editing-powered T-cell therapies for cancer and other serious diseases. PTX is developing a pipeline of other gene-edited T-cell therapies for the treatment of solid tumours and other blood cancers. The company is also developing a gene editing platform that can be used to develop gene editing therapies for a wide range of diseases.
What is PTX known for?
Snapshot
Public AU
Ownership
1986
Year founded
11
Employees
Melbourne, Australia
Head office
Loading Map...
Operations
All Locations
Melbourne, AU
Products and/or services of Prescient Therapeutics
- OmniCAR: an advanced, universal CAR platform, offering controllable T-cell activity and the ability to target multiple antigens with a single cell product.
- CellPryme: an advanced cell therapy enhancement platform designed to boost CAR-T effectiveness. It comprises two distinct components, each effective independently and synergistic when combined.
- PTX-100: a pioneering compound that inhibits the cancer growth enzyme GGT-1, disrupting oncogenic Ras pathways and inducing cancer cell apoptosis. It is the sole GGT-1 inhibitor in clinical development globally.
- PTX-200: a PH domain inhibitor that effectively blocks the Akt tumour survival pathway crucial in various cancers such as breast, ovarian, and leukaemia. PTX-200 acts specifically on Akt without affecting other kinases.
Prescient Therapeutics executive team
- Mr. James McDonnellChief Executive Officer
- Ms. Melanie Jaye Leydin B.Bus, C.A.CFO & Company Secretary
- Dr. Rebecca TunstallChief Operating Officer
- Dr. Marissa Lim M.B.A., MBBSChief Medical Officer